Differenze
Queste sono le differenze tra la revisione selezionata e la versione attuale della pagina.
| Entrambe le parti precedenti la revisione Revisione precedente Prossima revisione | Revisione precedente | ||
|
aree:proteomica:rppa:bibliografia [2017/02/18 22:36] Gianluca Frustagli Aggiunta dei primi 11 link |
aree:proteomica:rppa:bibliografia [2017/02/18 22:41] (versione attuale) Gianluca Frustagli |
||
|---|---|---|---|
| Linea 12: | Linea 12: | ||
| ===== Bibliografia ===== | ===== Bibliografia ===== | ||
| - | 1 Signore M et al. \\ | + | Signore M et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/27286453|UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/27286453|UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.]] \\ | ||
| <wrap lo>Oncotarget. 2016 Jul 12;7(28):44113-44128. doi: 10.18632/oncotarget.9859.</wrap> | <wrap lo>Oncotarget. 2016 Jul 12;7(28):44113-44128. doi: 10.18632/oncotarget.9859.</wrap> | ||
| - | 2 De Angelis ML et al. \\ | + | De Angelis ML et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/26956206|Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/26956206|Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.]] \\ | ||
| <wrap lo>Stem Cells Transl Med. 2016 Apr;5(4):511-23. doi: 10.5966/sctm.2015-0214.</wrap> | <wrap lo>Stem Cells Transl Med. 2016 Apr;5(4):511-23. doi: 10.5966/sctm.2015-0214.</wrap> | ||
| - | 3 Marziali G, Signore M et al. \\ | + | Marziali G, Signore M et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/26857460|Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/26857460|Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.]] \\ | ||
| <wrap lo>Sci Rep. 2016 Feb 9;6:21557. doi: 10.1038/srep21557.</wrap> | <wrap lo>Sci Rep. 2016 Feb 9;6:21557. doi: 10.1038/srep21557.</wrap> | ||
| - | 4 Trono P et al. \\ | + | Trono P et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/25961924|hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/25961924|hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.]] \\ | ||
| <wrap lo>Oncogene. 2016 Feb 18;35(7):887-96. doi: 10.1038/onc.2015.143. Epub 2015 May 11.</wrap> | <wrap lo>Oncogene. 2016 Feb 18;35(7):887-96. doi: 10.1038/onc.2015.143. Epub 2015 May 11.</wrap> | ||
| - | 5 Signore M et al. \\ | + | Signore M et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/24810059|Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/24810059|Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.]] \\ | ||
| <wrap lo>Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.</wrap> | <wrap lo>Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.</wrap> | ||
| - | 6 Forte S et al. \\ | + | Forte S et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/24349068|Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/24349068|Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model.]] \\ | ||
| <wrap lo>PLoS One. 2013 Dec 12;8(12):e81432. doi: 10.1371/journal.pone.0081432.</wrap> | <wrap lo>PLoS One. 2013 Dec 12;8(12):e81432. doi: 10.1371/journal.pone.0081432.</wrap> | ||
| - | 7 Sette G et al. \\ | + | Sette G et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/23056514|EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/23056514|EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential.]] \\ | ||
| <wrap lo>PLoS One. 2012;7(10):e46891. doi: 10.1371/journal.pone.0046891.</wrap> | <wrap lo>PLoS One. 2012;7(10):e46891. doi: 10.1371/journal.pone.0046891.</wrap> | ||
| - | 8 Francescangeli F et al. \\ | + | Francescangeli F et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/22753241|Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/22753241|Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.]] \\ | ||
| <wrap lo>Stem Cells. 2012 Sep;30(9):1819-30. doi: 10.1002/stem.1163.</wrap> | <wrap lo>Stem Cells. 2012 Sep;30(9):1819-30. doi: 10.1002/stem.1163.</wrap> | ||
| - | 9 Signore M, Reeder KA. \\ | + | Signore M, Reeder KA. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/22081344|Antibody validation by Western blotting.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/22081344|Antibody validation by Western blotting.]] \\ | ||
| <wrap lo>Methods Mol Biol. 2012;823:139-55. doi: 10.1007/978-1-60327-216-2_10.</wrap> | <wrap lo>Methods Mol Biol. 2012;823:139-55. doi: 10.1007/978-1-60327-216-2_10.</wrap> | ||
| - | 10 Napoletani D et al. \\ | + | Napoletani D et al. \\ |
| [[https://www.ncbi.nlm.nih.gov/pubmed/21439301|Homologous control of protein signaling networks.]] \\ | [[https://www.ncbi.nlm.nih.gov/pubmed/21439301|Homologous control of protein signaling networks.]] \\ | ||
| <wrap lo>J Theor Biol. 2011 Jun 21;279(1):29-43. doi: 10.1016/j.jtbi.2011.03.020.</wrap> | <wrap lo>J Theor Biol. 2011 Jun 21;279(1):29-43. doi: 10.1016/j.jtbi.2011.03.020.</wrap> | ||
| - | 11 VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. \\ | + | VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. \\ |
| - | [https://www.ncbi.nlm.nih.gov/pubmed/17892368[|Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.]] \\ | + | [[https://www.ncbi.nlm.nih.gov/pubmed/17892368|Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.]] \\ |
| <wrap lo>Expert Rev Mol Diagn. 2007 Sep;7(5):625-33. Review.</wrap> | <wrap lo>Expert Rev Mol Diagn. 2007 Sep;7(5):625-33. Review.</wrap> | ||
| Spreafico F et al. \\ | Spreafico F et al. \\ | ||
| - | [[|Proteomics analysis of cerebrospinal fluid from children with Central Nervous System tumors identifies candidate proteins relating to tumor metastatic spread.]] \\ | + | Proteomics analysis of cerebrospinal fluid from children with Central Nervous System tumors identifies candidate proteins relating to tumor metastatic spread. \\ |
| - | <wrap lo>Oncotarget (submitted, second round of revision)</wrap> | + | <wrap lo em>Oncotarget (submitted, second round of revision)</wrap> |
| Manic G & Signore M et al. \\ | Manic G & Signore M et al. \\ | ||
| - | [[|CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient hyperdiploid colorectal cancer stem cells.]] \\ | + | CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient hyperdiploid colorectal cancer stem cells. \\ |
| - | <wrap lo>Gut (submitted, second round of revision)</wrap> | + | <wrap lo em>Gut (submitted, second round of revision)</wrap> |
| Haas TL et al. \\ | Haas TL et al. \\ | ||
| - | [[|Identification of Integrin Alpha 7 as Functional Marker and Potential Therapeutic Target in Glioblastoma Multiforme.]] \\ | + | Identification of Integrin Alpha 7 as Functional Marker and Potential Therapeutic Target in Glioblastoma Multiforme. \\ |
| - | <wrap lo>Cell Stem Cell (submitted, second round of revision)</wrap> | + | <wrap lo em>Cell Stem Cell (submitted, second round of revision)</wrap> |
| - | FIXME Aggiungere link agli articoli | ||
